Biomarin Pharmaceutical Inc Sample Contracts

July 30th, 2021 · Common Contracts · 1000 similar
Biomarin Pharmaceutical Inc2 - SECTION 3. Conditions to Effectiveness. The effectiveness of the amendments set forth in Section 2 hereof are subject solely to satisfaction of the following conditions precedent (the date of such satisfaction being the “Amendment Effective...
August 11th, 2017 · Common Contracts · 897 similar
Biomarin Pharmaceutical IncBIOMARIN PHARMACEUTICAL INC. (a Delaware corporation)

BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of $450,000,000 aggregate principal amount of the Company’s 0.599% Senior Subordinated Convertible Notes due 2024 (the “Notes”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to pu

February 27th, 2009 · Common Contracts · 402 similar
Biomarin Pharmaceutical IncBIOMARIN PHARMACEUTICAL INC. a Delaware corporation and MELLON INVESTOR SERVICES LLC a New Jersey limited liability company as Rights Agent AMENDED AND RESTATED RIGHTS AGREEMENT Dated as of February 27, 2009

Amended and Restated Rights Agreement (the “Agreement”), dated as of February 27, 2009, between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Mellon Investor Services LLC, a New Jersey limited liability company as Rights Agent (the “Rights Agent”).

May 14th, 2020 · Common Contracts · 393 similar
Biomarin Pharmaceutical IncINDENTURE DATED AS OF MAY 14, 2020 BETWEEN BIOMARIN PHARMACEUTICAL INC. AND U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE 1.25% Convertible Senior Subordinated Notes due 2027

THIS INDENTURE (this “Indenture”), dated as of May 14, 2020, is between BioMarin Pharmaceutical Inc., a corporation duly organized under the laws of the State of Delaware (the “Company”), and U.S. Bank National Association, a national banking association, as Trustee (the “Trustee”).

March 28th, 2006 · Common Contracts · 263 similar
Biomarin Pharmaceutical IncBIOMARIN PHARMACEUTICAL INC. (a Delaware corporation) 9,000,000 Shares of Common Stock PURCHASE AGREEMENT
October 15th, 2013 · Common Contracts · 237 similar
Biomarin Pharmaceutical IncBioMarin Pharmaceutical Inc. INDENTURE Dated as of October 15, 2013 Wilmington Trust, National Association, a national banking association, as Trustee

Indenture dated as of October 15, 2013, between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), and Wilmington Trust, National Association, a national banking association (“Trustee”).

May 4th, 1999 · Common Contracts · 224 similar
Biomarin Pharmaceutical IncEXHIBIT 10.1 BIOMARIN PHARMACEUTICAL INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (the "AGREEMENT") is effective as of 1998, by and between Biomarin Pharmaceutical Inc., a Delaware corporation (the "COMPANY"), and ___________ (the...
August 11th, 2017 · Common Contracts · 141 similar
Biomarin Pharmaceutical IncBIOMARIN PHARMACEUTICAL INC., Issuer AND WILMINGTON TRUST, NATIONAL ASSOCATION, Trustee INDENTURE Dated as of August 11, 2017 Debt Securities

INDENTURE, dated as of August 11, 2017, among BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), and Wilmington Trust, National Association, as trustee (the “Trustee”):

October 11th, 2013 · Common Contracts · 126 similar
Biomarin Pharmaceutical IncOctober 8, 2013

The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between Barclays Bank PLC (“Dealer”) through its agent Barclays Capital Inc. (the “Agent”), and BioMarin Pharmaceutical Inc. (“Counterparty”). This communication constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Barclays Bank PLC is not a member of the Securities Investor Protection Corporation (“SIPC”). Barclays is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.

May 4th, 1999 · Common Contracts · 124 similar
Biomarin Pharmaceutical IncEXHIBIT 10.21 [LOGO OF AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION APPEARS HERE] STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE- GROSS (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. BASIC PROVISIONS ("BASIC PROVISIONS") 1.1 PARTIES: This...
December 4th, 2001 · Common Contracts · 69 similar
Biomarin Pharmaceutical IncUNDERWRITING AGREEMENT UNDERWRITING AGREEMENT
July 6th, 1999 · Common Contracts · 46 similar
Biomarin Pharmaceutical IncOF --
February 22nd, 2012 · Common Contracts · 37 similar
Biomarin Pharmaceutical IncLEASE SAN RAFAEL CORPORATE CENTER 790 Lindaro Street San Rafael, California SR CORPORATE CENTER PHASE TWO, LLC, a Delaware limited liability company as Landlord, and BIOMARIN PHARMACEUTICAL INC, a Delaware corporation as Tenant.

This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between SR CORPORATE CENTER PHASE TWO, LLC, a Delaware limited liability company (“Landlord”), and BIOMARIN PHARMACEUTICAL INC., a Delaware corporation (“Tenant”).

August 16th, 2001 · Common Contracts · 34 similar
Biomarin Pharmaceutical IncExhibit 1.2 COMMON STOCK PURCHASE AGREEMENT Dated as of August 15, 2001 by and between BIOMARIN PHARMACEUTICAL INC.
August 12th, 2003 · Common Contracts · 32 similar
Biomarin Pharmaceutical IncREGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of June 23, 2003, by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), and UBS Securities LLC and CIBC World Markets Corp. (collectively, the “Initial Purchasers”), for whom UBS Securities LLC is acting as representative, pursuant to that certain Purchase Agreement, dated as of June 18, 2003 (the “Purchase Agreement”) between the Company and the Initial Purchasers.

September 5th, 2012 · Common Contracts · 16 similar
Biomarin Pharmaceutical IncEMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (“Agreement”) made effective as of September 5, 2012 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Jeffrey R. Ajer (“Employee”).

November 26th, 2014 · Common Contracts · 13 similar
Biomarin Pharmaceutical IncPURCHASE AGREEMENT dated as of November 23, 2014 among PROSENSA HOLDING N.V., BIOMARIN PHARMACEUTICAL INC. and BIOMARIN FALCONS B.V.

This PURCHASE AGREEMENT (this “Agreement”) dated as of November 23, 2014, among Prosensa Holding N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the “Company”), BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”), and BioMarin Falcons B.V., a private company with limited liability (besloten vennootschap) organized under the laws of The Netherlands and a wholly owned indirect subsidiary of Parent (“Buyer”).

May 4th, 1999 · Common Contracts · 8 similar
Biomarin Pharmaceutical IncEXHIBIT 10.20 46 GALLI DRIVE, NOVATO, CALIFORNIA STANDARD NNN LEASE--MULTI- TENANT PROPERTY WITNESSETH
February 29th, 2016 · Common Contracts · 4 similar
Biomarin Pharmaceutical IncTERMINATION AND TRANSITION AGREEMENT by and between

This Termination and Transition Agreement (this “Agreement”), dated as of October 1, 2015 (the “Agreement Date”), is made by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”) and Ares Trading S.A., a corporation organized under the laws of Switzerland (“Merck Serono”). BioMarin and Merck Serono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

December 19th, 2016 · Common Contracts · 4 similar
Biomarin Pharmaceutical IncINDEMNIFICATION AGREEMENT

This Indemnification Agreement (this Agreement) dated as of ________________, 20__, is made by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the Company), and _________________ (Indemnitee).

February 27th, 2009 · Common Contracts · 3 similar
Biomarin Pharmaceutical IncAMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT

THIS AMENDMENT NO. 1 (the “Amendment”), dated January 16, 2009, amends that certain Securities Purchase Agreement, dated as of January 4, 2009 (the “Agreement”), by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Purchaser”).

May 4th, 1999 · Common Contracts · 3 similar
Biomarin Pharmaceutical IncEXHIBIT 10.5 BIOMARIN PHARMACEUTICAL INC. AMENDED AND RESTATED FOUNDER'S STOCK PURCHASE AGREEMENT THIS AGREEMENT (the "Agreement") is made between John Klock (the "Purchaser") and BIOMARIN PHARMACEUTICAL INC. (the "Company") as of October 1, 1997....
June 14th, 1999 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncEXHIBIT 10.27 BIOMARIN PHARMACEUTICAL INC. CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the "AGREEMENT") is made as of April 12, 1999, by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the...
May 18th, 2001 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncExhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT is entered into as of May 16, 2001 among BioMarin Pharmaceutical Inc., a Delaware corporation (the "Company"), and the other Persons listed on Annex A hereto (sometimes...
July 21st, 1999 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncCONFIDENTIAL ------------
July 6th, 1999 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncEXHIBIT 10.30 OPERATING AGREEMENT
February 26th, 2010 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncCONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]. Redacted portions filed separately with Confidential Treatment Application. STOCK PURCHASE AGREEMENT by and among BIOMARIN PHARMACEUTICAL INC., HUXLEY PHARMACEUTICALS, INC....

THIS STOCK PURCHASE AGREEMENT is made and entered into as of October 20, 2009, by and among BioMarin Pharmaceutical Inc., a Delaware corporation (the “Purchaser”), Huxley Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the stockholders of the Company set forth on the signature pages hereto (collectively the “Stockholders” and individually, a “Stockholder”).

June 2nd, 2004 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncASSET PURCHASE AGREEMENT among MEDICIS PHARMACEUTICAL CORPORATION, a Delaware corporation, ASCENT PEDIATRICS, INC., a Delaware corporation, BIOMARIN PHARMACEUTICAL INC., a Delaware corporation and BIOMARIN PEDIATRICS INC., a Delaware corporation

This Asset Purchase Agreement is entered into as of April 20, 2004, by and among Medicis Pharmaceutical Corporation, a Delaware corporation (“Medicis”), Ascent Pediatrics, Inc., a Delaware corporation (“Ascent”), BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), and BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin (“BioMarin Acquisition”). Capitalized terms used in this Agreement are defined herein and in Exhibit A.

June 1st, 2005 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncAGREEMENT

This Agreement, dated as of May 27, 2005 (this “Agreement”), by and among Caduceus Capital Master Fund Limited, Caduceus Capital II, L.P., OrbiMed Advisors LLC (“OrbiMed Advisors”) and OrbiMed Capital LLC (collectively, along with their respective Associates and Affiliates, as hereinafter defined, the “Caduceus Group”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), sets forth the parties’ agreement with respect to the nominees for director at the Company’s 2005 Annual Meeting of Stockholders (the “Annual Meeting”) and various other matters related thereto and described below.

February 27th, 2009 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncCONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] LA JOLLA PHARMACEUTICAL COMPANY SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 4, 2009, is executed by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and BioMarin Pharmaceutical Inc., a Delaware corporation (the “Purchaser”).

June 2nd, 2004 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncLICENSE AGREEMENT

This LICENSE AGREEMENT (“Agreement”) is entered into as of May 18, 2004 (the “Effective Date”) by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin (“BioMarin Acquisition” or “Licensee”), Medicis Pharmaceutical Corporation, a Delaware corporation (“Medicis”), and Ascent Pediatrics, Inc., a Delaware corporation (“Ascent” or “Licensor”), a wholly-owned subsidiary of Medicis. Each is referred to herein as a “Party” and collectively as the “Parties.”

June 2nd, 2004 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncSECURITIES PURCHASE AGREEMENT among MEDICIS PHARMACEUTICAL CORPORATION, a Delaware corporation, ASCENT PEDIATRICS, INC., a Delaware corporation, BIOMARIN PHARMACEUTICAL INC., a Delaware corporation and BIOMARIN PEDIATRICS INC., a Delaware corporation...

This Securities Purchase Agreement is entered into as of May 18, 2004 (the “Effective Date”), by and among Medicis Pharmaceutical Corporation, a Delaware corporation (“Medicis”), Ascent Pediatrics, Inc., a Delaware corporation (“Ascent”), BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), and BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin (“BioMarin Acquisition”). Capitalized terms used in this Agreement are defined herein and in Exhibit A.

December 12th, 2014 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncMUTUAL NON-DISCLOSURE AGREEMENT

This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Netherlands corporation with offices at J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands. (“Prosensa”). Each of BioMarin and Prosensa may be referred to herein as a “Party” or collectively as the “Parties.”

December 23rd, 2008 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncAMENDED AND RESTATED EMPLOYMENT AGREEMENT

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) made as of May 11, 2005 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with its principal executive offices located at 105 Digital Drive, Novato, California 94949 (the “Company”) and Jean-Jacques Bienaimé (“Employee”), residing at 2510 Skyfarm Drive, Hillsborough, CA 94010 is hereby amended and restated, effective January 1, 2009, primarily to reflect the changes resulting from Amendment No. 2 to this Agreement, dated May 10, 2006, and the requirements of the final regulations under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).

July 21st, 1999 · Common Contracts · 2 similar
Biomarin Pharmaceutical IncCONFIDENTIAL ------------